The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended granting a marketing authorization for Ireland-headquartered Shire’s (LSE: SHP) Intuniv (guanfacine). 26 July 2015
AC Immune on Thursday said it has received a milestone payment from the Swiss drug major Roche Group (VTX: ROG), which has now started a Phase III trial of AC Immune’s crenezumab to treat Alzheimer’s disease. 23 July 2015
Two treatments for Alzheimer’s disease have shown promise and achieved positive Phase II/IIb trial results, as announced at the Alzheimer’s Association International Conference. 22 July 2015
Eli Lilly has released much anticipated new data on its investigational Alzheimer’s disease drug solanezumab at a press conference at the Alzheimer’s Association International Conference in Washington ahead of the presentation. 22 July 2015
The US Food and Drug Administration has granted orphan drug designation to investigational recombinant humanized anti-tau antibody, C2N-8E12 (ABBV-8E12), from US drugmaker AbbVie and C2N Diagnostics. 20 July 2015
A rise in prescription charges in England, the National Health service budget squeeze, the government’s promotion of self-care and self-medication, and the switching of some prescription medicines to over-the-counter (OTC) products have led to an increase in demand for OTC pharmaceuticals. 20 July 2015
Edison Investment Research has lowered its valuation on Swedish drug developer Orexo to 173 Swedish kronor per share primarily driven by revised outlook for its Zubsolv tablet. 16 July 2015
Sumitomo Dainippon Pharma has concluded a license agreement with the Australian subsidiary of independent French peer Servier relating to marketing, sales and distribution in Australia of Latuda (lurasidone hydrochloride). 15 July 2015
In a move that confirms the continuation of the biotech acquisition boom, US major Celgene late yesterday revealed it had entered into a definitive agreement to acquire Receptos. 15 July 2015
New Zealand’s Pharmaceutical Management Agency PHARMAC is seeking feedback on a proposal relating to the funding of the TNF-inhibitor medicines and gabapentin used to treat epilepsy and neuropathic pain. 14 July 2015
The global market for myasthenia gravis therapeutics is anticipated to more than treble in value from $146.4 million in 2014 to $550.4 million by 2024. 14 July 2015
There are currently 420 medicines in the American biopharma pipeline for neurological disorders, including epilepsy, Alzheimer’s and multiple sclerosis. 14 July 2015
AC Immune says it has received a milestone from Genentech in its collaboration agreement for anti-Tau antibodies for the treatment of Alzheimer’s disease and other neurodegenerative diseases. 13 July 2015
The US Food and Drug Administration has approved Rexulti (brexpiprazole), from Japanese drugmaker Otsuka and Danish CNS specialist Lundbeck. 11 July 2015
US biotech major Biogen announced on Friday that head of R&D Douglas Williams will leave the company at the end of July to become chief executive of an as-yet unnamed start-up biotechnology company. 11 July 2015
USA-based Depomed says the Patent Trial and Appeal Board (PTAB) of the US Patent and Trademark Office issued its final decision in the inter partes review proceedings (IPRs) initiated by privately-held US drugmaker Purdue Pharma against two Depomed patents (US Patent Nos 6,340,475 and 6,635,280). 10 July 2015
Israel-based generics giant Teva Pharmaceutical Industries has launched its generic version of the migraine drug Axert (almotriptan malate) tablets in the USA. 9 July 2015
The European Commission has announced that Hetlioz (tasimelteon) from US pharma company Vanda Pharmaceuticals has been approved to treat non-24-hour sleep-wake disorder in totally blind adults. 8 July 2015
Allergan (NYSE: AGN) has entered into an agreement to acquire exclusive worldwide rights to US pharma giant Merck & Co's investigational small molecule oral calcitonin gene-related peptide (CGRP) receptor antagonists. 7 July 2015
Today, the US Food and Drug Administration approved Miplyffa (arimoclomol), an oral medication for the treatment of Neimann-Pick disease, type C (NPC). 20 September 2024
US neuroscience company BioXcel Therapeutics has announced a new clinical prioritization and an update on its late-stage development programs for the treatment of agitation with BXCL501. 20 September 2024
Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US clinical stage CNS drug developer Athira Pharma is taking decisive action following the company’s announcement of disappointing data from the Phase II/III LIFT-AD clinical trial of fosgonimeton to treat Alzheimer’s disease (AD). 18 September 2024
The US Food and Drug Administration (FDA) has approved Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS), from Swiss pharma giant Roche. 16 September 2024
US pharma major Eli Lilly has announced a $1 billion expansion of its manufacturing site in Limerick, Ireland, to increase production of biologic active ingredients, including those for its recently approved treatment for early symptomatic Alzheimer's disease. 13 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024
The global migraine market in mature economies is projected to grow from $9.2 billion in 2023 to $16.4 billion by 2033, according to a report from GlobalData. 10 September 2024
Cartesian Therapeutics today announced that the US Food and Drug Administration (FDA) has granted Rare Pediatric Disease designation to Descartes-08 for the treatment of juvenile dermatomyositis (JDM). 9 September 2024
California’s Lykos Therapeutics is still trying to regroup after being rocked by the US Food and Drug Administration’s (FDA) rejection of midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD). 6 September 2024
The cost of prescribed dependency-forming medicines has decreased by £410 million ($539.6 million) since 2015/16, according to newly released data from the UK’s National Health Service (NHS). 6 September 2024
Shares in US biopharma Axsome Therapeutics, a biopharmaceutical company developing and delivering novel therapies for the management of CNS disorders, closed 7% higher on Wednesday. 5 September 2024
Mid-Atlantic BioTherapeutics (MABT) has announced a collaboration with Accelero Biostructures to identify novel inhibitors of USP30, a protein linked to neurological disorders and other conditions. 5 September 2024
Praxis Precision Medicines shared positive top-line results for its Phase II, proof of concept study evaluating relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathy (DEE) patients. 4 September 2024